A Phase 2/3 interventional study of Spesolimab and Placebo in Colitis, Ulcerative, sponsored by Boehringer Ingelheim. Completed at 54 sites in 12 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-10-16.
Sponsored by Boehringer Ingelheim · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 615 studies in Colitis, Ulcerative with a site in United States — 115 open to participants now, 167 under way, 34 of them phase 3. Colitis, Ulcerative · United States.
Among the 615 studies in Colitis, Ulcerative with a site in United States, this one is the 233rd largest by enrollment of the 499 interventional ones that give a count, is one of 34 that started in 2018, is one of 16 in phase 2/3, and was the 302nd registered.
1,857 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →115 of the 615 studies in Colitis, Ulcerative with a site in United States are open now. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in United States
Ages 16–80
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Sites in United States
Ages 18–85
University of Minnesota · Sites in United States
Ages 18+
Muhammad N Aslam, MD · Sites in United States
Ages 18–80
Vanda Pharmaceuticals · Sites in United States
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 305 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 135 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
615 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 87 · Phase 2 173 · Phase 3 132 · Phase 4 33
First in 1995; this study’s year is marked. 34 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 98 is above the median of 70 across 1,239 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 76 across the 499 interventional studies, 198 across the 113 observational. Of the 407 that completed or were terminated, 192 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
332 of 615 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Boehringer Ingelheim has 5 studies filed under Colitis, Ulcerative — fewer than ten, so there is no comparison to draw.
55 of the studies in Colitis, Ulcerative with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06589986Phase 3Hoffmann-La RocheA Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis | 2027-01-30 |
| NCT06260163Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis | 2027-02-10 |
| NCT04624230Phase 3PfizerEvaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis | 2027-03-17 |
| NCT03006068Phase 3AbbVieA Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | 2027-07 |
| NCT06880744Phase 3AbbVieA Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab | 2027-08 |
Add all 55 to your calendar (.ics) → With an account.
Among the 615 studies in Colitis, Ulcerative with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial has two sequentially enrolling parts with different objectives. The primary objectives of this trial are
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo
Drug: Spesolimab
Drug: Spesolimab
Drug: Spesolimab
Solution for infusion
Solution for infusion
Proportion of Patients With Clinical Remission at Week 12
Proportion of patients with clinical remission (defined as modified Mayo Clinical Score (MCS) ≤ 2, with Stool Frequency Score (SFS) = 0 or 1 \[if drop ≥1 from baseline\] and Rectal Bleeding Score (RBS) = 0 and modified Endoscopic Subscore (mESS) ≤ 1) at week 12. Proportion of patients was calculated as n/N, with n=number of patients with clinical remission at week 12 and N=number analyzed. 95% Confidence Intervals (CI) were calculated using the method of Wilson.
Time frame: At week 12.
Proportion of Patients With Clinical Response at Week 12
Proportion of patients with clinical response (defined as Rectal Bleeding Score (RBS) ≤ 1 or decrease by ≥1 from baseline; and total Mayo Clinical Score (MCS) decrease by ≥ 3 and 30% from baseline) at week 12. Proportion of patients is calculated as n/N, with n=number of patients with clinical response at week 12 and N=number of patients analyzed. 95% Confidence Intervals (CI) are calculated using the method of Wilson.
Time frame: At week 12.
Proportion of Patients With Endoscopic Improvement at Week 12
Proportion of patients with endoscopic improvement at week 12 (defined as modified Endoscopic Subscore (mESS) ≤ 1) Proportion of patients was calculated as n/N, with n=number of patients with Endoscopic Improvment at Week 12 and N=number analysed. 95% Confidence Intervals (CI) were calculated using the method of Wilson.
Time frame: At week 12.
Proportion of Patients With Combined Endoscopic Improvement and Histologic Remission at Week 12
Proportion of patients with combined endoscopic improvement and histologic remission at week 12 (defined as modified Endoscopic Subscore (mESS) ≤ 1 and Robarts Histology Index ≤ 6). Proportion of patients was calculated as n/N, with n= number of patients with Endoscopic Improvement and histologic remission at week 12 and N=number of patients analysed.
Time frame: At week 12.
Change in Inflammatory Bowel Disease Questionnaire (IBDQ) Score From Baseline at Week 12
Change in Inflammatory Bowel Disease Questionnaire (IBDQ) score from baseline at Week 12. The IBDQ is a 32-item self-report questionnaire for patients with IBD to evaluate the patient reported outcomes across 4 dimensions: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). The response options describe the magnitude or frequency of impairment from 1 (most severe) to 7 (no impairment). The items are summed up, resulting in a sum score ranging from 32 to 224 points, with higher scores indicating better outcomes. A score change of 16 is reported to reflect the minimal clinically important difference (MCID). Mean is adjusted mean.
Time frame: At baseline and at week 12.
Phase II/III randomized, placebo-controlled, double-blind trial to assess the safety and efficacy of spesolimab induction therapy in patients with moderate-to-severely active ulcerative colitis who have failed previous biologics therapy. Phase III was not conducted, due to recruitment issues in Phase II.
| Milestone | Placebo | 300 mg Spesolimab (BI 655130) SD | 450 mg Spesolimab (BI 655130) q4w | 1200 mg Spesolimab (BI 655130) q4w |
|---|---|---|---|---|
| Started | 23 | 24 | 23 | 28 |
| Treated | 23 | 24 | 23 | 27 |
| Completed | 18 | 21 | 22 | 20 |
| Not completed | 5 | 3 | 1 | 8 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 | 3 |
| Withdrew: Adverse event | 2 | 2 | 0 | 3 |
| Withdrew: Withdrawal by subject | 2 | 1 | 0 | 1 |
| Withdrew: Withdrawn by principle investigator | 1 | 0 | 0 | 0 |
| Withdrew: Not treated | 0 | 0 | 0 | 1 |
Proportion of patients with clinical remission (defined as modified Mayo Clinical Score (MCS) ≤ 2, with Stool Frequency Score (SFS) = 0 or 1 \[if drop ≥1 from baseline\] and Rectal Bleeding Score (RBS) = 0 and modified Endoscopic Subscore (mESS) ≤ 1) at week 12. Proportion of patients was calculated as n/N, with n=number of patients with clinical remission at week 12 and N=number analyzed. 95% Confidence Intervals (CI) were calculated using the method of Wilson.
| Proportion of Participants | Placebo | 300 mg Spesolimab (BI 655130) SD | 450 mg Spesolimab (BI 655130) q4w | 1200 mg Spesolimab (BI 655130) q4w |
|---|---|---|---|---|
| Proportion of Patients With Clinical Remission at Week 12 | 0.00 (0.000 to 0.143) | 0.042 (0.007 to 0.202) | 0.087 (0.024 to 0.268) | 0.071 (0.020 to 0.226) |
Proportion of patients with clinical response (defined as Rectal Bleeding Score (RBS) ≤ 1 or decrease by ≥1 from baseline; and total Mayo Clinical Score (MCS) decrease by ≥ 3 and 30% from baseline) at week 12. Proportion of patients is calculated as n/N, with n=number of patients with clinical response at week 12 and N=number of patients analyzed. 95% Confidence Intervals (CI) are calculated using the method of Wilson.
| Proportion of participants | Placebo | 300 mg Spesolimab (BI 655130) SD | 450 mg Spesolimab (BI 655130) q4w | 1200 mg Spesolimab (BI 655130) q4w |
|---|---|---|---|---|
| Proportion of Patients With Clinical Response at Week 12 | 0.217 (0.097 to 0.419) | 0.167 (0.067 to 0.359) | 0.261 (0.125 to 0.465) | 0.250 (0.127 to 0.434) |
Proportion of patients with endoscopic improvement at week 12 (defined as modified Endoscopic Subscore (mESS) ≤ 1) Proportion of patients was calculated as n/N, with n=number of patients with Endoscopic Improvment at Week 12 and N=number analysed. 95% Confidence Intervals (CI) were calculated using the method of Wilson.
| Proportion of participants | Placebo | 300 mg Spesolimab (BI 655130) SD | 450 mg Spesolimab (BI 655130) q4w | 1200 mg Spesolimab (BI 655130) q4w |
|---|---|---|---|---|
| Proportion of Patients With Endoscopic Improvement at Week 12 | 0.000 (0.000 to 0.143) | 0.083 (0.023 to 0.258) | 0.087 (0.024 to 0.268) | 0.071 (0.020 to 0.226) |
Proportion of patients with combined endoscopic improvement and histologic remission at week 12 (defined as modified Endoscopic Subscore (mESS) ≤ 1 and Robarts Histology Index ≤ 6). Proportion of patients was calculated as n/N, with n= number of patients with Endoscopic Improvement and histologic remission at week 12 and N=number of patients analysed.
| Proportion of participants | Placebo | 300 mg Spesolimab (BI 655130) SD | 450 mg Spesolimab (BI 655130) q4w | 1200 mg Spesolimab (BI 655130) q4w |
|---|---|---|---|---|
| Proportion of Patients With Combined Endoscopic Improvement and Histologic Remission at Week 12 | 0.00 (0.000 to 0.143) | 0.083 (0.023 to 0.258) | 0.043 (0.008 to 0.210) | 0.036 (0.006 to 0.177) |
Change in Inflammatory Bowel Disease Questionnaire (IBDQ) score from baseline at Week 12. The IBDQ is a 32-item self-report questionnaire for patients with IBD to evaluate the patient reported outcomes across 4 dimensions: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). The response options describe the magnitude or frequency of impairment from 1 (most severe) to 7 (no impairment). The items are summed up, resulting in a sum score ranging from 32 to 224 points, with higher scores indicating better outcomes. A score change of 16 is reported to reflect the minimal clinically important difference (MCID). Mean is adjusted mean.
| Score on a scale | Placebo | 300 mg Spesolimab (BI 655130) SD | 450 mg Spesolimab (BI 655130) q4w | 1200 mg Spesolimab (BI 655130) q4w |
|---|---|---|---|---|
| Change in Inflammatory Bowel Disease Questionnaire (IBDQ) Score From Baseline at Week 12 | 19.8 (4.7 to 35.0) | 19.5 (4.6 to 34.5) | 21.2 (6.6 to 35.9) | 20.8 (6.3 to 35.4) |
Collected over From screening until end of study, up to 29 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/23 (0%) | 4/23 (17.4%) | 5/23 (21.7%) |
| 300 mg Spesolimab (BI 655130) SD | 0/24 (0%) | 3/24 (12.5%) | 7/24 (29.2%) |
| 450 mg Spesolimab (BI 655130) q4w | 0/23 (0%) | 2/23 (8.7%) | 7/23 (30.4%) |
| 1200 mg Spesolimab (BI 655130) q4w | 0/27 (0%) | 3/27 (11.1%) | 17/27 (63%) |
| Event | Placebo | 300 mg Spesolimab (BI 655130) SD | 450 mg Spesolimab (BI 655130) q4w | 1200 mg Spesolimab (BI 655130) q4w |
|---|---|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 1/23 | 2/24 | 1/23 | 2/27 |
| AnaemiaBlood and lymphatic system disorders | 1/23 | 0/24 | 0/23 | 1/27 |
| Iron deficiency anaemiaBlood and lymphatic system disorders | 0/23 | 0/24 | 1/23 | 0/27 |
| Clostridium difficile colitisInfections and infestations | 1/23 | 0/24 | 0/23 | 0/27 |
| Femur fractureInjury, poisoning and procedural complications | 1/23 | 0/24 | 0/23 | 0/27 |
| Infusion related reactionInjury, poisoning and procedural complications | 1/23 | 1/24 | 0/23 | 0/27 |
| OsteonecrosisMusculoskeletal and connective tissue disorders | 1/23 | 0/24 | 0/23 | 0/27 |
| Event | Placebo | 300 mg Spesolimab (BI 655130) SD | 450 mg Spesolimab (BI 655130) q4w | 1200 mg Spesolimab (BI 655130) q4w |
|---|---|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 0/23 | 2/24 | 1/23 | 6/27 |
| AnaemiaBlood and lymphatic system disorders | 5/23 | 1/24 | 0/23 | 0/27 |
| Feeling hotGeneral disorders | 0/23 | 0/24 | 3/23 | 0/27 |
| HeadacheNervous system disorders | 0/23 | 0/24 | 1/23 | 3/27 |
| NasopharyngitisInfections and infestations | 0/23 | 2/24 | 2/23 | 1/27 |
| ErythemaSkin and subcutaneous tissue disorders | 0/23 | 0/24 | 2/23 | 0/27 |
| RashSkin and subcutaneous tissue disorders | 0/23 | 1/24 | 2/23 | 2/27 |
| SyncopeNervous system disorders | 0/23 | 2/24 | 0/23 | 0/27 |
| Abdominal pain upperGastrointestinal disorders | 0/23 | 0/24 | 0/23 | 2/27 |
| ConstipationGastrointestinal disorders | 0/23 | 0/24 | 0/23 | 2/27 |
Randomised Set: The RS included all randomised patients. Treatment assignment was as randomised. It was the main analysis set for presentation of efficacy on binary endpoints.
| Age, Continuous(Years) | Placebo | 300 mg Spesolimab (BI 655130) SD | 450 mg Spesolimab (BI 655130) q4w | 1200 mg Spesolimab (BI 655130) q4w | Total |
|---|---|---|---|---|---|
| Mean | 42.2 ± 14.1 | 41.4 ± 14.6 | 42.3 ± 15.3 | 43.9 ± 14.9 | 42.5 ± 14.6 |
| Sex: Female, Male(Participants) | Placebo | 300 mg Spesolimab (BI 655130) SD | 450 mg Spesolimab (BI 655130) q4w | 1200 mg Spesolimab (BI 655130) q4w | Total |
|---|---|---|---|---|---|
| Female | 11 | 7 | 10 | 8 | 36 |
| Male | 12 | 17 | 13 | 20 | 62 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | 300 mg Spesolimab (BI 655130) SD | 450 mg Spesolimab (BI 655130) q4w | 1200 mg Spesolimab (BI 655130) q4w | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 1 | 1 |
| Not Hispanic or Latino | 23 | 24 | 23 | 27 | 97 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | 300 mg Spesolimab (BI 655130) SD | 450 mg Spesolimab (BI 655130) q4w | 1200 mg Spesolimab (BI 655130) q4w | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 1 |
| Asian | 4 | 1 | 4 | 5 | 14 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 | 1 | 3 |
| White | 18 | 23 | 18 | 21 | 80 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency
Ran from Mar 2018 to primary completion in May 2020, 25 months.
Results were first posted in Jun 2021, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Spesolimab